Liver fibrosis is a pathological condition characterized by the excessive deposition
of extracellular matrix material by activated hepatic stellate cells (HSCs). We recently
reported that activation of the aryl hydrocarbon receptor (AhR), a ligand-activated
transcription factor, with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) increases
HSC activation in vitro and in mouse models of experimental liver fibrosis.
The goal of this project was to determine the mechanism by which AhR activation impacts
HSC activation and the subsequent development of liver fibrosis. It is possible that
HSCs are direct cellular targets for TCDD. Alternatively, TCDD could increase HSC
activation indirectly by exacerbating hepatocyte damage and inflammation. To investigate
this, we generated mice in which the AhR was selectively removed from either hepatocytes
or HSCs to determine the ramifications on liver injury, inflammation, and HSC activation
in an experimental model of liver fibrosis elicited by chronic administration of TCDD.
Results from these studies indicate that TCDD does not directly activate HSCs in the mouse
liver to produce fibrosis. Instead, it appears that TCDD-induced changes in hepatocytes,
such as the development of steatosis, are what ultimately stimulate HSC activation and produce
fibrosis. A second focus of this project was to investigate an endogenous role for AhR signaling
in the regulation of HSC activation in the absence of liver injury and inflammation. To this end,
I used CRISPR/Cas9 technology to knock down the AhR in the human HSC cell line, LX-2. I
discovered that a functional AhR is required for optimal proliferation of activated HSCs.
However, other endpoints of HSC activation, such as the production of collagen type I, were
not impacted by the removal of AhR signaling. These findings are important because the AhR has
been shown to be a druggable target, and there is growing interest in therapeutically modulating
AhR activity to prevent or reverse HSC activation. Collectively, results from this project
indicate that therapeutically targeting AhR signaling in hepatocytes, instead of AhR signaling
in HSCs, might be a preferred approach for limiting HSC activation and preventing or diminishing liver fibrosis.